Am J Perinatol 2004; 21(6): 365-368
DOI: 10.1055/s-2004-831885
Copyright © 2004 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Late-Onset Mycobacterium abscessus Sepsis in a Very Low Birthweight Premature Infant: Diagnostic and Therapeutic Challenges

M. Cecilia Di Pentima1 , Robin Doyle1 , Robert Locke1 , Deborah Tuttle1
  • 1Christiana Hospital and A. I. duPont Hospital for Children, Thomas Jefferson University, Wilmington, Delaware
Further Information

Publication History

Publication Date:
16 August 2004 (online)

Late-onset sepsis (after 3 days of life) is a frequent a complication found in very low birth weight (VLBW, 1000 to 1500 g) premature infants. We report the second case of late-onset sepsis caused by an uncommon pathogen, Mycobacterium abscessus.

REFERENCES

  • 1 Speert D P, Munson D, Mitchell C et al.. Mycobacterium chelonei septicemia in a premature infant.  J Pediatr. 1980;  96 681-683
  • 2 Tashjian J H, Coulam C B, Washington II J A. Vaginal flora in asymptomatic women.  Mayo Clin Proc. 1976;  51 557-561
  • 3 Phillips M S, von Reyn C F. Nosocomial infections due to nontuberculous mycobacteria.  Clin Infect Dis. 2001;  33 1363-1374
  • 4 Kusunoki S, Ezaki T. Proposal of Mycobacterium peregrinum sp. nov., nom. rev., and elevation of Mycobacterium chelonae subsp. abscessus (Kubica et al.) to species status: Mycobacterium abscessus comb. nov.  Int J Syst Bacteriol. 1992;  42 240-245
  • 5 Yakrus M A, Hernandez S M, Floyd M M, Sikes D, Butler W R, Metchock B. Comparison of methods for identification of Mycobacterium abscessus and M. chelonae isolates.  J Clin Microbiol. 2001;  39 4103-4110
  • 6 Brown BA W R. Infections due to nontuberculous Mycobacteria. In: Mandell GL BJ, Dolin R Principles and Practice of Infectious Diseases. Vol. II. Philadelphia; Curchill Livingstone 2000: 2631-2636
  • 7 Brown-Elliott B A, Wallace Jr R J. Clarithromycin resistance to Mycobacterium abscessus .  J Clin Microbiol. 2001;  39 2745-2746
  • 8 Brown B A, Wallace Jr R J, Onyi G O, De Rosas V, Wallace III R J. Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and M. chelonae-like organisms.  Antimicrob Agents Chemother. 1992;  36 180-184
  • 9 Woods G L, Brown-Elliot B A, Desmond E P et al.. Susceptibility testing of Mycobacteria, Nocardiae, and other aerobic actinomycetes; approved standard. Wayne, PA: National Committee for Clinical Laboratory Standards 2003: 25-37
  • 10 Fernandez-Roblas R, Esteban J, Cabria F, Lopez J C, Jimenez M S, Soriano F. In vitro susceptibilities of rapidly growing mycobacteria to telithromycin (HMR 3647) and seven other antimicrobials.  Antimicrob Agents Chemother. 2000;  44 181-182
  • 11 Brown-Elliott B A, Wallace Jr R J, Crist C J, Mann L, Wilson R W. Comparison of in vitro activities of gatifloxacin and ciprofloxacin against four taxa of rapidly growing mycobacteria.  Antimicrob Agents Chemother. 2002;  46 3283-3285
  • 12 Wallace Jr R J, Brown-Elliott B A, Crist C J, Mann L, Wilson R W. Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria.  Antimicrob Agents Chemother. 2002;  46 3164-3167

M. Cecilia Di PentimaM.D. M.P.H. 

Christiana Hospital and A. I. duPont Hospital for Children, Thomas Jefferson University

1600 Rockland Road, Wilmington, DE

    >